Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
复制标题
术前血浆内皮糖蛋白水平可预测根治性前列腺切除术后的生化进展。
DOI:
10.1158/1078-0432.ccr-07-4707
复制
发表时间:
2008
期刊:
影响因子:
--
通讯作者:
Shariat,ShahrokhF
中科院分区:
文献类型:
--
作者:
Svatek,RobertS;Karam,JoseA;Roehrborn,ClausG;Karakiewicz,PierreI;Slawin,KevinM;Shariat,ShahrokhF
Purpose:Endoglin (CD105) is a transmembrane glycoprotein expressed by human vascular endothelial cells thought to play a pivotal role in endothelial cell proliferation. The aim of this study was to evaluate the association of preoperative plasma endoglin levels with established clinical and pathologic features of prostate cancer and disease progression after radical prostatectomy.Experimental Design:Preoperative plasma endoglin levels were measured in 425 patients who underwent radical prostatectomy for clinically localized prostate cancer using a commercially available ELISA assay. Multivariate logistic regression was used to test the association of plasma endoglin levels with biochemical progression after radical prostatectomy.Results:Median follow-up for patients alive at the time of analysis was 36.8 months (interquartile range, 44.1). Of 425 patients, 77 patients (18.1%) experienced biochemical progression after radical prostatectomy. Preoperative plasma endoglin levels were significantly elevated in patients with higher preoperative total serum prostate-specific antigen (P< 0.001) and adverse pathologic features. Preoperative plasma endoglin was an independent predictor of biochemical progression after surgery after adjusting for the effects of standard preoperative and postoperative features (P< 0.001 andP= 0.026, respectively).Conclusions:Preoperative plasma endoglin levels are associated with established features of advanced prostate cancer. More importantly, higher preoperative plasma endoglin levels are independent predictors of an increased risk of biochemical progression in patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy.